NCT06870903

Brief Summary

The aim of this study is to compare two types of lymphadenectomy (transperitoneal vs. paracervical) during the lymphadenectomy phase of endometrial cancer staging surgery performed using V-NOTES, a new and advanced technique. This study seeks to optimize the V-NOTES technique for endometrial cancer staging. This randomized, prospective, controlled study will include patients diagnosed with endometrial cancer via histology, following physical examination and imaging, and who are electively scheduled for the V-NOTES endometrial cancer staging procedure. Patients will be randomized into two groups: the transvaginal paracervical lymphadenectomy group and the transperitoneal lymphadenectomy group. The parameters related with surgical and functional outcomes will be compared in both groups.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
52

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 25, 2025

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 11, 2025

Completed
4 days until next milestone

Study Start

First participant enrolled

March 15, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2026

Completed
Last Updated

March 20, 2025

Status Verified

March 1, 2025

Enrollment Period

10 months

First QC Date

February 25, 2025

Last Update Submit

March 17, 2025

Conditions

Keywords

endometrial cancerV-NOTESlymphadenectomysentinel lymph nodetransperitonealextraperitoneal

Outcome Measures

Primary Outcomes (15)

  • Total operation duration

    The total duration of the operation in minutes

    During surgery

  • Duration of right and left lymphadenectomy

    The duration of lymphadenectomies in minutes

    During surgery

  • Number of lymph nodes excised

    Lymph node count in the pathology report

    Postoperative second week

  • number of positive lymph nodes

    Sentinel positive lymph nodes in the pathology report

    Postoperative second week

  • Hospitalization duration

    Number of days patients stayed at the hospital postoperatively

    During hospital stay

  • Total bleeding volume

    Measured by the suction bottle's volume and number of surgical gauzse used during surgery

    During surgery

  • Difference between pre- and postoperative hemoglobin values

    Hemoglobin level (g/dL)

    Postoperative 1st day

  • Surgical complications

    Clavien dindo scale of surgical complications

    During hospital stay

  • Location o SLN

    The area that sentinel lymph node detected internal iliac, external iliac ,bifurcation or obturator fossa

    During surgery

  • Preoperative and postoperative hematocrit values

    Hematocrit level (%)

    During hospital stay

  • Tumor's patological features

    Histophatology, grade, lymphovascular invasion, tumor diameter(cm), myometrial invasion, stage, total positive lymph node count

    Postoperative second week

  • Management of complications

    intraoperative and postoperative complication's management

    through study completion

  • Duration of lateral colpotomy

    at transvaginal retroperitoneal procedure ; before the lymphadenectomy we are making and incision to the lateral of cervix .this time describes the time that to reach the obturator fossa to pick the nodes.

    During surgery

  • Duration of hysterectomy

    minutes

    During surgery

  • Sentinel lymphnode's side and number

    number

    Postoperative second week

Secondary Outcomes (7)

  • Postoperative pain

    3rd and 6th month after operation

  • Sexual function

    at postoperative 3rd and 6th month

  • Timing of passing gas

    During hospital stay

  • Demographic features

    Postoperative second week

  • Previous abdominal surgery

    Preoperative day

  • +2 more secondary outcomes

Study Arms (2)

transvaginal paracervical sentinel lymphadenectomy group

EXPERIMENTAL

Surgical Procedure of transvaginal sentinel lymphadenectomy group: All patients will be operated in accordance with Memorial Sloan Kettering Cancer Center procedure. V-NOTES will consist of transvaginal paracervical sentinel lymph node (SLN) mapping followed by V-NOTES hysterectomy and bilateral salpingo-oophorectomy (BSO). SLN Mapping: Under general anesthesia, subjects will be placed in supine lithotomy position. Methylene blue solution (BLUMET IV INJECTION INJECTABLE 50 mg/5 ml 1x5 ml) (1 mL submucosal to the cervix at the 3 and 9 o'clock positions and 1 mL at a depth of 1-2 cm, using a total volume of 2-4 mL. Monitoring of lymphatic ducts includes identification of structures stained with methylene blue dye in the expected anatomical location, typically between the internal and external iliac veins or in the obturator region. Bilateral and symmetrical structures believed to be sentinel lymph nodes (SLNs) will be removed. When unilate

Procedure: Extraperitoneal(transvaginal paracervical sentinel lymphadenectomy) group lymphadenectomy

Transperitoneal lymphadenectomy

ACTIVE COMPARATOR

In this arm, patients will undergo transperitoneal lymphadenectomy with V-NOTES. The procedure begins with methylene blue injection for sentinel lymph nodes. Methylene blue will be injected at the 3 and 9 o'clock positions on the cervix, first at a depth of 1 mm and then at 4 mm, with 1 cc administered at each point. This will result in a total of 4 cc (1 cc x 4). Then, the procedure will continue with anterior and posterior colpotomies, followed by placement of the V-NOTES apparatus. Hysterectomy is performed first, followed by peritoneal dissection and lymph node excision.

Procedure: Transperitoneal lymphadenectomy

Interventions

The procedure begins with a vaginal incision in the lateral vaginal fornices (on both sides), which is then extended to allow placement of the V-NOTES apparatus. By identifying an appropriate cleavage plane, the obturator fossa is accessed to excise the obturator lymph nodes. Following this, an anterior colpotomy is performed to access the vesicocervical space, and a posterior colpotomy is made to open the rectouterine pouch. The V-NOTES apparatus is then placed to continue with the hysterectomy and bilateral salpingo-oophorectomy (BSO).

transvaginal paracervical sentinel lymphadenectomy group

In this arm, patients will undergo transperitoneal lymphadenectomy with V-NOTES. The procedure begins with anterior and posterior colpotomies, followed by placement of the V-NOTES apparatus. Hysterectomy is performed first, followed by peritoneal dissection and lymph node excision.

Transperitoneal lymphadenectomy

Eligibility Criteria

Age18 Years - 85 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants whose endometrial biopsy resulted in endometrial cancer and whose disease will be detected limited to the uterus using imaging modalities (computed tomography \[CT\], magnetic resonance imaging or Fluorine-18 fluorodeoxyglucose positron emission tomography/CT)
  • Absence of synchronous malignancies.
  • No neoadjuvant treatment before surgical intervention.

You may not qualify if:

  • Contraindications to using methylene blue dye or contraindications to the vNOTES procedure.
  • Patients who have had previous malignancy surgery.
  • Severe, deeply penetrating endometriosis or enlarged uterus that may require forced vaginal extraction
  • Receiving neodajuvant therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gazi Yasargil Training And Research Hospital

Diyarbakır, Baglar, 21090, Turkey (Türkiye)

RECRUITING

Related Publications (3)

  • Deng L, Liu Y, Yao Y, Deng Y, Tang S, Sun L, Wang Y. Efficacy of vaginal natural orifice transluminal endoscopic sentinel lymph node biopsy for endometrial cancer: a prospective multicenter cohort study. Int J Surg. 2023 Oct 1;109(10):2996-3002. doi: 10.1097/JS9.0000000000000551.

    PMID: 37335988BACKGROUND
  • Can B, Akgol S, Adiguzel O, Kaya C. A new, less invasive approach for retroperitoneal pelvic and para-aortic lymphadenectomy combining the transvaginal natural orifice transluminal endoscopic surgery (vNOTES) technique and single-port laparoscopy. Int J Gynecol Cancer. 2024 May 6;34(5):789-790. doi: 10.1136/ijgc-2023-005093. No abstract available.

    PMID: 38316443BACKGROUND
  • Baekelandt J, Jespers A, Huber D, Badiglian-Filho L, Stuart A, Chuang L, Ali O, Burnett A. vNOTES retroperitoneal sentinel lymph node dissection for endometrial cancer staging: First multicenter, prospective case series. Acta Obstet Gynecol Scand. 2024 Jul;103(7):1311-1317. doi: 10.1111/aogs.14843. Epub 2024 Apr 16.

    PMID: 38623778BACKGROUND

MeSH Terms

Conditions

Endometrial Neoplasms

Condition Hierarchy (Ancestors)

Uterine NeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Behzat Can, Assoc. Prof.

    Health Sciences University Gazi Yasargil Training and Research Hospital

    STUDY CHAIR
  • Sedat Akgol, Assoc. Prof.

    Health Sciences University Gazi Yasargil Training and Research Hospital

    STUDY DIRECTOR
  • Kevser Arkan, MD

    Health Sciences University Gazi Yasargil Training and Research Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Gynecology Oncology Department

Study Record Dates

First Submitted

February 25, 2025

First Posted

March 11, 2025

Study Start

March 15, 2025

Primary Completion

December 31, 2025

Study Completion

March 1, 2026

Last Updated

March 20, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will share

All IPD that underlie results in a publication will be shared.

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
It will be shared when the study is published.
Access Criteria
When the study is published, the data will be shared by the corresponding author on request.

Locations